{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:31:57Z","timestamp":1789061517934,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Resveratrol and quercetin have effects on polycystic ovary syndrome (PCOS). Hence, resveratrol combined with quercetin may have better effects on it. However, because of the limitations in animal and human experiments, the pharmacological and molecular mechanism of quercetin-resveratrol combination (QRC) remains to be clarified. In this research, a systematic pharmacological approach comprising multiple compound target collection, multiple potential target prediction, and network analysis was used for comparing the characteristic of resveratrol, quercetin and QRC, and exploring the mechanism of QRC. After that, four networks were constructed and analyzed: (1) compound-compound target network; (2) compound-potential target network; (3) QRC-PCOS PPI network; (4) QRC-PCOS-other human proteins (protein-protein interaction) PPI network. Through GO and pathway enrichment analysis, it can be found that three compounds focus on different biological processes and pathways; and it seems that QRC combines the characteristics of resveratrol and quercetin. The in-depth study of QRC further showed\u00a0 more PCOS-related biological processes and pathways. Hence, this research\u00a0not only offers clues to the researcher who is interested in comparing the differences among resveratrol, quercetin and QRC, but also provides hints for the researcher who wants to explore QRC\u2019s various synergies and its pharmacological and molecular mechanism.<\/jats:p>","DOI":"10.1038\/s41598-019-54408-3","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T11:02:42Z","timestamp":1575543762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Exploring the Pharmacological Mechanism of Quercetin-Resveratrol Combination for Polycystic Ovary Syndrome: A Systematic Pharmacological Strategy-Based Research"],"prefix":"10.1038","volume":"9","author":[{"given":"Kailin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-8760","authenticated-orcid":false,"given":"Liuting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,5]]},"reference":[{"key":"54408_CR1","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1210\/jc.2003-032046","volume":"89","author":"R Azziz","year":"2004","unstructured":"Azziz, R. et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab. 89, 2745\u20132749 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR2","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/humrep\/dep399","volume":"25","author":"WA March","year":"2010","unstructured":"March, W. A. et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum. Reprod. 25, 544\u2013551 (2010).","journal-title":"Hum. Reprod."},{"key":"54408_CR3","first-page":"774","volume":"18","author":"A Dunaif","year":"1997","unstructured":"Dunaif, A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocrine Rev. 18, 774\u2013800 (1997).","journal-title":"Endocrine Rev."},{"key":"54408_CR4","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/humrep\/15.6.1266","volume":"15","author":"LC Morin-Papunen","year":"2000","unstructured":"Morin-Papunen, L. C. et al. Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome. Human Reprod. 15, 1266\u20131274 (2000).","journal-title":"Human Reprod."},{"key":"54408_CR5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2362.2006.01712.x","volume":"36","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis, E. et al. Inflammatory and endothelial markers in women with polycystic ovary syndrome. Eur. J. Clin. Invest. 36, 691\u2013697 (2006).","journal-title":"Eur. J. Clin. Invest."},{"key":"54408_CR6","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","volume":"95","author":"RA Wild","year":"2010","unstructured":"Wild, R. A. et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: A consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J. Clin. Endocrinol. Metab. 95, 2038\u20132049 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12020-009-9268-x","volume":"37","author":"Y Mu","year":"2009","unstructured":"Mu, Y. et al. Interleukin 1 beta (IL-1\u03b2) promoter C [\u2212511] T polymorphism but not C [+3953] T polymorphism is associated with polycystic ovary syndrome. Endocrine. 37, 71\u20135 (2009).","journal-title":"Endocrine."},{"key":"54408_CR8","first-page":"2304","volume":"85","author":"JK Wickenheisser","year":"2000","unstructured":"Wickenheisser, J. K. et al. Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J. Clin. Endocrinol. Metab. 85, 2304\u20132311 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR9","first-page":"2317","volume":"83","author":"R Azziz","year":"1998","unstructured":"Azziz, R. et al. Adrenal androgen excess in the polycystic ovary syndrome: Sensitivity and responsivity of the hypothalamic-pituitary-adrenal axis. J. Clin. Endocrinol. Metab. 83, 2317\u20132323 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR10","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1177\/1933719116667218","volume":"24","author":"Z Wang","year":"2017","unstructured":"Wang, Z. et al. Quercetin Decreases Insulin Resistance in a Polycystic Ovary Syndrome Rat Model by Improving Inflammatory Microenvironment. Reprod Sci. 24, 682\u2013690 (2017).","journal-title":"Reprod Sci."},{"key":"54408_CR11","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1210\/jc.2016-1858","volume":"101","author":"B Banaszewska","year":"2016","unstructured":"Banaszewska, B. et al. Effects of Resveratrol on Polycystic Ovary Syndrome: A Double-blind, Randomized, Placebo-controlled Trial. J. Clin. Endocrinol. Metab. 101, 4322\u20134328 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR12","doi-asserted-by":"publisher","unstructured":"Bahramrezaie, M. et al. Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial.J Assist Reprod Genet, https:\/\/doi.org\/10.1007\/s10815-019-01461-6 (2019).","DOI":"10.1007\/s10815-019-01461-6"},{"key":"54408_CR13","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1933719115570900","volume":"22","author":"M Ergenoglu","year":"2015","unstructured":"Ergenoglu, M. et al. Effects of Resveratrol on Ovarian Morphology, Plasma Anti-Mullerian Hormone, IGF-1 Levels, and Oxidative Stress Parameters in a Rat Model of Polycystic Ovary Syndrome. Reprod. Sci. 22, 942\u20137, https:\/\/doi.org\/10.1177\/1933719115570900 (2015).","journal-title":"Reprod. Sci."},{"key":"54408_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-0042-118705","volume":"49","author":"N Rezvan","year":"2017","unstructured":"Rezvan, N. et al. Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial. Horm. Metab. Res. 49, 115\u2013121, https:\/\/doi.org\/10.1055\/s-0042-118705 (2017).","journal-title":"Horm. Metab. Res."},{"key":"54408_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3109\/13880209.2015.1091482","volume":"54","author":"KN Shah","year":"2016","unstructured":"Shah, K. N. & Patel, S. S. Phosphatidylinositide 3-kinase inhibition: A new potential target for the treatment of polycystic ovarian syndrome. Pharm. Biol. 54, 975\u201383, https:\/\/doi.org\/10.3109\/13880209.2015.1091482 (2016).","journal-title":"Pharm. Biol."},{"issue":"2","key":"54408_CR16","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70(2), 440\u20136, https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-1947 (2010).","journal-title":"Cancer Res."},{"issue":"22","key":"54408_CR17","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.1158\/0008-5472.CAN-17-1662","volume":"77","author":"Y Guo","year":"2017","unstructured":"Guo, Y. et al. Multiscale modeling of inflammation-inducedtumorigenesis reveals competing oncogenic and oncoprotective roles forinflammation. Cancer research 77(22), 6429\u20136441 (2017).","journal-title":"Cancer research"},{"key":"54408_CR18","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acssynbio.8b00237","volume":"8","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Network-based combinatorial CRISPR-Cas9 screens identify synergistic modules inhuman cells. ACS Synthetic Biology 8, 482\u2013490 (2019).","journal-title":"ACS Synthetic Biology"},{"key":"54408_CR19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1758-2946-6-13","volume":"6","author":"J Ru","year":"2014","unstructured":"Ru, J. et al. TCMSP: a database of systematic pharmacology for drug discovery from herbal medicines. J. Cheminform. 6, 13 (2014).","journal-title":"J. Cheminform."},{"key":"54408_CR20","doi-asserted-by":"crossref","first-page":"W609","DOI":"10.1093\/nar\/gkq300","volume":"38","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Res. 38, W609\u2013W614 (2010).","journal-title":"Nucleic Acids Res."},{"key":"54408_CR21","doi-asserted-by":"crossref","first-page":"D514","DOI":"10.1093\/nar\/gki033","volume":"33","author":"A Hamosh","year":"2005","unstructured":"Hamosh, A. et al. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res. 33, D514\u20137 (2005).","journal-title":"Nucleic Acids Res."},{"key":"54408_CR22","doi-asserted-by":"crossref","first-page":"D447","DOI":"10.1093\/nar\/gku1003","volume":"43","author":"D Szklarczyk","year":"2015","unstructured":"Szklarczyk, D. et al. STRING v10:protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447\u2013D452 (2015).","journal-title":"Nucleic Acids Res."},{"key":"54408_CR23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"DW Huang","year":"2009","unstructured":"Huang, D. W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44\u201357 (2009).","journal-title":"Nat. Protoc."},{"key":"54408_CR24","doi-asserted-by":"publisher","first-page":"e1000350","DOI":"10.1371\/journal.pcbi.1000350","volume":"5","author":"PV Missiuro","year":"2009","unstructured":"Missiuro, P. V. et al. Information flow analysis of interactome networks. PLoS Comput. Biol. 5, e1000350, https:\/\/doi.org\/10.1371\/journal.pcbi.1000350 (2009).","journal-title":"PLoS Comput. Biol."},{"issue":"7","key":"54408_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17139-x","volume":"2018","author":"L Zeng","year":"2018","unstructured":"Zeng, L., Yang, K. & Ge, J. Uncovering the Pharmacological Mechanism of Astragalus Salvia Compound on Pregnancy-Induced Hypertension Syndrome by a Network Pharmacology Approach. Sci Rep 2018(7), 16849, https:\/\/doi.org\/10.1038\/s41598-017-17139-x (2018).","journal-title":"Sci Rep"},{"key":"54408_CR26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barab\u00e1si","year":"2011","unstructured":"Barab\u00e1si, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12, 56\u201368, https:\/\/doi.org\/10.1038\/nrg2918 (2011).","journal-title":"Nat. Rev. Genet."},{"key":"54408_CR27","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0140-6736(03)14410-8","volume":"362","author":"LJ Webber","year":"2003","unstructured":"Webber, L. J. et al. Formation and early development of follicles in the polycystic ovary. Lancet. 362, 1017\u20131021 (2003).","journal-title":"Lancet."},{"key":"54408_CR28","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1210\/jc.2007-0729","volume":"92","author":"SA Stubbs","year":"2007","unstructured":"Stubbs, S. A. et al. Abnormal preantral folliculogenesis in polycystic ovaries is associated with increased granulosa cell division. J. Clin. Endocrinol. Metab. 92, 4418\u20134426 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR29","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/humupd\/dmn015","volume":"14","author":"S Franks","year":"2008","unstructured":"Franks, S., Stark, J. & Hardy, K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod. Update. 14, 367\u2013378 (2008).","journal-title":"Hum Reprod. Update."},{"key":"54408_CR30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1210\/mend.13.6.0311","volume":"13","author":"VL Nelson","year":"1999","unstructured":"Nelson, V. L. et al. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol. Endocrinol. 13, 946\u2013957 (1999).","journal-title":"Mol. Endocrinol."},{"key":"54408_CR31","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.fertnstert.2008.06.035","volume":"91","author":"R Azziz","year":"2009","unstructured":"Azziz, R. et al. Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess PCOS Society. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 91, 456\u2013488 (2009).","journal-title":"Fertil Steril."},{"key":"54408_CR32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/09513598709023610","volume":"1","author":"MG Hull","year":"1987","unstructured":"Hull, M. G. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol. 1, 235\u2013245 (1987).","journal-title":"Gynecol Endocrinol."},{"key":"54408_CR33","first-page":"1158","volume":"79","author":"C Gilling-Smith","year":"1994","unstructured":"Gilling-Smith, C., Willis, D. S., Beard, R. W. & Franks, S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 79, 1158\u20131165 (1994).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR34","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3904\/kjim.2010.25.2.119","volume":"25","author":"K Choi","year":"2010","unstructured":"Choi, K. & Kim, Y. B. Molecular mechanism of insulin resistance in obesity and type 2 diabetes. Korean. J. Intern. Med. 25, 119\u2013129 (2010).","journal-title":"Korean. J. Intern. Med."},{"key":"54408_CR35","first-page":"1241","volume":"76","author":"NM O'Meara","year":"1993","unstructured":"O'Meara, N. M. et al. Defects in \u03b2-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab 76, 1241\u20131247 (1993).","journal-title":"J. Clin. Endocrinol. Metab"},{"key":"54408_CR36","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2003.08.002","volume":"14","author":"S Sam","year":"2003","unstructured":"Sam, S. & Dunaif, A. Polycystic ovary syndrome: syndrome XX? Trends. Endocrinol. Metab. 14, 365\u2013370 (2003).","journal-title":"Trends. Endocrinol. Metab."},{"key":"54408_CR37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/humrep\/deh609","volume":"20","author":"S Rice","year":"2005","unstructured":"Rice, S. et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum. Reprod. 20, 373\u2013381 (2005).","journal-title":"Hum. Reprod."},{"key":"54408_CR38","first-page":"117","volume":"16","author":"B Cheatham","year":"1995","unstructured":"Cheatham, B. & Kahn, C. R. Insulin action and the insulin signaling network. Endocr. Rev. 16, 117\u2013142 (1995).","journal-title":"Endocr. Rev."},{"key":"54408_CR39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1210\/jc.2008-1492","volume":"94","author":"TP Ciaraldi","year":"2009","unstructured":"Ciaraldi, T. P. et al. Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance. J. Clin. Endocrinol. Metab. 94, 157\u2013163 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54408_CR40","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.2337\/diab.41.10.1257","volume":"41","author":"A Dunaif","year":"1992","unstructured":"Dunaif, A. et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 41, 1257\u20131266 (1992).","journal-title":"Diabetes."},{"issue":"3","key":"54408_CR41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513590.2011.583955","volume":"28","author":"A Makker","year":"2012","unstructured":"Makker, A., Goel, M. M., Das, V. & Agarwal, A. Pi3k-akt-mtor and mapk signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update. Gynecological Endocrinology 28(3), 175\u2013181 (2012).","journal-title":"Gynecological Endocrinology"},{"key":"54408_CR42","doi-asserted-by":"publisher","unstructured":"Hu, M. et al. Perturbed ovarian and uterine glucocorticoid receptor signaling accompanies the balanced regulation of mitochondrial function and NF\u03baB-mediated inflammation under conditions of hyperandrogenism and insulin resistance. Life Sci. 116681, https:\/\/doi.org\/10.1016\/j.lfs.2019.116681 (2019 Jul 23).","DOI":"10.1016\/j.lfs.2019.116681"},{"key":"54408_CR43","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/j.1471-0528.2006.00990.x","volume":"113","author":"R Pasquali","year":"2006","unstructured":"Pasquali, R., Gambineri, A. & Pagotto, U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 113, 1148\u20131159 (2006).","journal-title":"BJOG."},{"key":"54408_CR44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI25102","volume":"115","author":"KE Wellen","year":"2005","unstructured":"Wellen, K. E. & Hotamisligil, G. S. Inflammation, stress, and diabetes. J. Clin. Invest. 115, 1111\u20131119 (2005).","journal-title":"J. Clin. Invest."},{"key":"54408_CR45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1196\/annals.1365.015","volume":"1092","author":"E Diamanti-Kandarakis","year":"2006","unstructured":"Diamanti-Kandarakis, E., Paterakis, T. & Kandarakis, H. A. Indices of low-grade inflammation in polycystic ovary syndrome. Ann. NY. Acad. Sci. 1092, 175\u2013186 (2006).","journal-title":"Ann. NY. Acad. Sci."},{"key":"54408_CR46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1210\/edrv-12-1-3","volume":"12","author":"L Poretsky","year":"1991","unstructured":"Poretsky, L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr. Rev. 12, 3\u201313 (1991).","journal-title":"Endocr. Rev."},{"key":"54408_CR47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0026-0495(99)90100-2","volume":"48","author":"F Gonzalez","year":"1999","unstructured":"Gonzalez, F. et al. Elevated serum levels of tumor necrosis factor \u03b1 in normal-weight women with polycystic ovary syndrome. Metabolism 48, 437\u2013441 (1999).","journal-title":"Metabolism"},{"key":"54408_CR48","doi-asserted-by":"crossref","first-page":"D590","DOI":"10.1093\/nar\/gky962","volume":"47","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. et al. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 47, D590\u2013D595 (2019).","journal-title":"Nucleic Acids Res."},{"key":"54408_CR49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 28, 27\u201330 (2000).","journal-title":"Nucleic Acids Res."},{"key":"54408_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","volume":"30","author":"S Palomba","year":"2009","unstructured":"Palomba, S., Falbo, A., Zullo, F. & Orio, F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr. Rev 30, 1\u201350 (2009).","journal-title":"Endocr. Rev"},{"key":"54408_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/1757-2215-7-21","volume":"7","author":"I Ortega","year":"2014","unstructured":"Ortega, I. et al. Resveratrol potentiates effects of simvastatin on inhibition of rat ovarian theca-interstitial cells steroidogenesis. J. Ovarian Res. 7, 21, https:\/\/doi.org\/10.1186\/1757-2215-7-21 (2014).","journal-title":"J. Ovarian Res."},{"key":"54408_CR52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jri.2006.08.002","volume":"73","author":"A Kolbus","year":"2007","unstructured":"Kolbus, A. et al. Interleukin-1 alpha but not interleukin-1 beta gene polymorphism is associated with polycystic ovary syndrome. J. Reprod. Immunol. 73, 188\u201393 (2007).","journal-title":"J. Reprod. Immunol."},{"key":"54408_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.fertnstert.2012.08.004","volume":"98","author":"I Ortega","year":"2012","unstructured":"Ortega, I. et al. Effects of resveratrol on growth and function of rat ovarian granulosa cells. Fertil. Steril. 98, 1563\u201373, https:\/\/doi.org\/10.1016\/j.fertnstert.2012.08.004 (2012).","journal-title":"Fertil. Steril."},{"issue":"2","key":"54408_CR54","doi-asserted-by":"publisher","first-page":"165","DOI":"10.22038\/IJBMS.2017.24801.6167","volume":"221","author":"M Ghowsi","year":"2018","unstructured":"Ghowsi, M., Khazali, H. & Sisakhtnezhad, S. Evaluation of TNF-\u03b1 and IL-6 mRNAs expressions in visceral and subcutaneous adipose tissues of polycystic ovarian rats and effects of resveratrol. Iran J Basic Med Sci. 221(2), 165\u2013174, https:\/\/doi.org\/10.22038\/IJBMS.2017.24801.6167 (2018).","journal-title":"Iran J Basic Med Sci."},{"issue":"3","key":"54408_CR55","doi-asserted-by":"crossref","first-page":"149","DOI":"10.29252\/ijrm.16.3.149","volume":"16","author":"M Ghowsi","year":"2018","unstructured":"Ghowsi, M., Khazali, H. & Sisakhtnezhad, S. The effect of resveratrol on oxidative stress in the liver and serum of a rat model of polycystic ovary syndrome: An experimental study. Int J Reprod Biomed (Yazd). 16(3), 149\u2013158 (2018).","journal-title":"Int J Reprod Biomed (Yazd)."},{"key":"54408_CR56","doi-asserted-by":"publisher","unstructured":"Neisy, A., Zal, F., Seghatoleslam, A. & Alaee, S. Amelioration by quercetin of insulin resistance and uterine GLUT4 and ER\u03b1 gene expression in rats with polycystic ovary syndrome (PCOS). Reprod Fertil Dev. 31(2), 315\u2013323, https:\/\/doi.org\/10.1071\/RD18222 (2019 Jan).","DOI":"10.1071\/RD18222"},{"issue":"1","key":"54408_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0427-7","volume":"11","author":"S Furat Rencber","year":"2018","unstructured":"Furat Rencber, S. et al. Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. J Ovarian Res. 11(1), 55, https:\/\/doi.org\/10.1186\/s13048-018-0427-7 (2018).","journal-title":"J Ovarian Res."},{"key":"54408_CR58","doi-asserted-by":"publisher","unstructured":"Bahramrezaie, M. et al. Khodarahmian M1, Pooladi A.Effects of resveratrol on VEGF & HIF1 genes expression in granulosa cells in the angiogenesis pathway and laboratory parameters of polycystic ovary syndrome: a triple-blind randomized clinical trial. J Assist Reprod Genet, https:\/\/doi.org\/10.1007\/s10815-019-01461-6 (2019).","DOI":"10.1007\/s10815-019-01461-6"},{"key":"54408_CR59","doi-asserted-by":"publisher","unstructured":"Khorshidi, M. et al. The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome. Phytother Res. 2018 Nov, 32(11), 2282\u20132289, https:\/\/doi.org\/10.1002\/ptr.6166. Epub 2018 Jul 30.","DOI":"10.1002\/ptr.6166."},{"issue":"1","key":"54408_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-018-0400-5","volume":"11","author":"S Jahan","year":"2018","unstructured":"Jahan, S. et al. Almajwal A3, Razak S4,5. Therapeutic potentials of Quercetin in management of polycystic ovarian syndrome using Letrozole induced rat model: a histological and a biochemical study. J Ovarian Res. 11(1), 26, https:\/\/doi.org\/10.1186\/s13048-018-0400-5 (2018).","journal-title":"J Ovarian Res."},{"key":"54408_CR61","first-page":"8","volume":"2017","author":"L Zhao","year":"2017","unstructured":"Zhao, L. et al. A combination of quercetin and resveratrol reduces obesity in high-fat diet-fed rats by modulation of gut microbiota. Food & Function 2017, 8 (2017).","journal-title":"Food & Function"},{"issue":"6","key":"54408_CR62","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jnutbio.2015.01.002","volume":"26","author":"U Etxeberria","year":"2015","unstructured":"Etxeberria, U. et al. Reshaping Faecal Gut Microbiota Composition by the Intake of Trans-Resveratrol and Quercetin in High-Fat Sucrose Diet-Fed Rats. The Journal of Nutritional Biochemistry 26(6), 651\u2013660 (2015).","journal-title":"The Journal of Nutritional Biochemistry"},{"issue":"6","key":"54408_CR63","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.3892\/etm.2017.5331","volume":"14","author":"L Zhao","year":"2017","unstructured":"Zhao, L. et al. Ombination treatment with quercetin and resveratrol attenuates high fat diet-induced obesity and associated inflammation in rats via the AMPK\u03b11\/SIRT1 signaling pathway. Exp Ther Med. 14(6), 5942\u20135948, https:\/\/doi.org\/10.3892\/etm.2017.5331 (2017).","journal-title":"Exp Ther Med."},{"issue":"1","key":"54408_CR64","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00394-015-0854-9","volume":"55","author":"N Arias","year":"2016","unstructured":"Arias, N., Macarulla, M. T., Aguirre, L., Milton, I. & Portillo, M. P. The combination of resveratrol and quercetin enhances the individual effects of these molecules on triacylglycerol metabolism in white adipose tissue. European Journal of Nutrition 55(1), 341\u2013348 (2016).","journal-title":"European Journal of Nutrition"},{"key":"54408_CR65","doi-asserted-by":"publisher","unstructured":"Peredo-Esc\u00e1rcega, A. E. et al. The Combination of Resveratrol and Quercetin Attenuates Metabolic Syndrome in Rats by Modifying the Serum Fatty Acid Composition and by Upregulating SIRT 1 and SIRT 2 Expression in White Adipose Tissue. Evid Based Complement Alternat Med. 474032, https:\/\/doi.org\/10.1155\/2015\/474032 (2015).","DOI":"10.1155\/2015\/474032"},{"issue":"7","key":"54408_CR66","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.3390\/ijms17071069","volume":"17","author":"C-T Vicente","year":"2016","unstructured":"Vicente, C.-T. et al. The Effect of Resveratrol and Quercetin Treatment on PPAR Mediated Uncoupling Protein (UCP-) 1, 2, and 3 Expression in Visceral White Adipose Tissue from Metabolic Syndrome Rats. International Journal of Molecular Sciences 17(7), 1069 (2016).","journal-title":"International Journal of Molecular Sciences"}],"updated-by":[{"DOI":"10.1038\/s41598-020-59780-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54408-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54408-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T17:06:40Z","timestamp":1671296800000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54408-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,5]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54408"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54408-3","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-020-59780-z","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,5]]},"assertion":[{"value":"21 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18420"}}